A Study of Evacetrapib in High-Risk Vascular Disease (ACCELERATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01687998
Recruitment Status : Terminated (Study termination due to insufficient efficacy.)
First Posted : September 19, 2012
Last Update Posted : December 13, 2016
The Cleveland Clinic
Information provided by (Responsible Party):
Eli Lilly and Company

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Terminated
  Actual Primary Completion Date : March 2016
  Actual Study Completion Date : July 2016
  Certification/Extension First Submitted : August 13, 2016

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 February 18, 2018 March 21, 2018
2 April 13, 2018